Clinical Trial

Phase II/III Randomized Trial of UC-MSC Secretome vs Sodium Hyaluronate in Knee Osteoarthritis

Study acronym: SECRET-OA
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, multicenter Phase II/III clinical trial designed to evaluate the effectiveness and safety of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome compared with sodium hyaluronate in patients with knee osteoarthritis. Knee osteoarthritis is a common degenerative joint disease that causes chronic pain and functional limitation. Participants will be randomly assigned to receive intra-articular injections of either UC-MSC-derived secretome or sodium hyaluronate. The study aims to assess improvements in knee pain, physical function, and overall clinical outcomes, as well as to evaluate the safety of the interventions over the study period.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-12-16 -> 2026-09-16 2026-05-13
minor Completion pushed: 2027-06-17 -> 2027-12-24 2026-05-13
Trial Details
NCT Number NCT07337863
Lead Sponsor Universitas Sriwijaya
Collaborators: PT Bifarma Adiluhung
Conditions Knee Osteoarthritis (Knee OA)
Enrollment 50 participants
Start Date 2026-08-30
Primary Completion 2026-09-16 (estimated)
Study Completion 2027-12-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-12